Skip to main content
. 2019 Nov 30;11(24):12844–12861. doi: 10.18632/aging.102557

Figure 3.

Figure 3

Treatment with senomorphics to inhibit SASP factors in senescent cells (1). Over time, these cells will be removed by immune cells (2). Finally, a regenerative process will lead to normal tissue functions (3). In aged or immunosuppressed individuals, this strategy would lead to an accumulation of SASP-silenced/attenuated senescent cells (4).